Ozanimod is primarily used in the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It works by modulating the immune system, specifically by targeting sphingosine-1-phosphate receptors, which helps reduce the migration of lymphocytes into the central nervous system. This action decreases inflammation and prevents further damage to nerve cells, thereby slowing the progression of the disease and reducing the frequency of relapses. Additionally, ozanimod has shown potential in treating ulcerative colitis, an inflammatory bowel disease, by similarly modulating immune responses to reduce inflammation in the gastrointestinal tract. Its oral administration offers a convenient treatment option for patients, improving adherence and quality of life.